Role of Particle Therapy for Intrahepatic Cholangiocarcinoma; Meta-Analysis for Comparison with Standard Therapy: TRP-Intrahepatic Cholangiocarcinoma 2025

粒子疗法在肝内胆管癌治疗中的作用;与标准疗法比较的荟萃分析:TRP-肝内胆管癌 2025

阅读:1

Abstract

INTRODUCTION: Particle therapy (PT) for intrahepatic cholangiocarcinoma is expected to provide good local control. However, it is difficult to compare PT with the current standard treatment modalities, surgery, and chemotherapy. Therefore, we conducted a meta-analysis and systematic review of the literature to compare PT with surgery and drug therapy. METHODS: A meta-analysis was performed using studies from 2010 to 2024 in which PT or surgery or drug therapy was performed for intrahepatic cholangiocarcinoma. 40 articles (7 PT, 13 surgery, 19 drug therapy, one surgery, and drug therapy) were selected based on used of radial surgery or first-line drug therapy. PT was basically for unresectable cases, and 80% of drug therapy cases had distant metastases. RESULTS: Forty selected articles found 1-3-year OS rates (PT vs. surgery vs. drug therapy) of 70.7% (95% CI: 64.2-76.1%) vs. 78.6% (74.2-82.3%) (p = 0.1198) vs. 49.0% (43.4-54.4%) (p = 0.0001); 47.1% (40.9-53.0%) vs. 56.3% (48.8-63.1%) (p = 0.1265) vs. 25.3% (19.7-31.3%) (p = 0.0011); and 36.6% (27.0-46.3%) vs. 46.8% (41.7-51.6%) (p = 0.1213) vs. 14.7% (8.3-22.7%) (p = 0.0021), respectively. And the 1-3-year local control rates for PT were 89.4% (95% CI: 81.3-94.1%), 74.6% (63.0-83.1%) and 67.1% (51.4-78.7%), respectively. Meta-regression analysis was performed using modality (PT vs. surgery vs. drug therapy), male: female ratio, and median age as risk factors. The results showed no significant difference between surgery and PT, but drug therapy showed significantly lower 1- and 2-year OS rates and median survival time, and a trend toward lower 3-year OS. CONCLUSION: The results of this analysis suggest that PT for intrahepatic cholangiocarcinoma may be one of the standard treatments in unresectable cases and in combination with drug therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。